Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.
SOURCE UCB, Inc.
-- UCB-sponsored data include the first presentation of investigational data of VIMPAT (lacosamide) as monotherapy for the treatment of partial-onset seizures in adults with epilepsy
ATLANTA, Nov. 20, 2013 /PRNewswire/ -- UCB, a global biopharmaceutical company focusing on CNS and immunology treatment and research, will be sponsoring 15 data presentations at the 67th Annual Meeting of the American Epilepsy Society in Washington, D.C., December 610. The poster presentations on VIMPAT (lacosamide) C-V include investigational data evaluating VIMPAT as monotherapy and further studies of VIMPAT as add-on therapy for the treatment of partial-onset seizures in adults with epilepsy.
VIMPAT is indicated as an adjunctive therapy for the treatment of partial-onset seizures in adults with epilepsy (ages >/= 17 in the U.S., ages >/= 16 years in the EU).1,2 The most common adverse reactions reported in pivotal trials and occurring in 10 percent or more of VIMPAT-treated patients, and greater than placebo, were dizziness, headache, nausea, and diplopia. Lacosamide is not currently approved as monotherapy. Additional important safety information for VIMPAT is available below.1,2
"The multiple data sets being presented at this year's AES meeting demonstrate UCB's ongoing investment in epilepsy research as part of our long-standing commitment to address unmet needs of people living with epilepsy," said Professor Dr. Iris Loew-Friedrich, Chief Medical Officer and Executive Vice President, UCB. "We continue to work with experts in the scientific community to expand our understanding of the efficacy and safety of VIMPAT, and we look forward to sharing the primary efficacy and safety data from our conversion to lacosamide monotherapy study of adults living with partial-onset seizures."
Investigational data will also be presented on brivaracetam, which is being studied as adjunctive therapy for the treatment of partial-onset seizures in adults with epilepsy. Additionally, results from three new epilepsy surveys, a study seeking to identify predictive factors for epilepsy management and an overview of a unique outcomes research partnership between academia and industry will be presented.
Following is a guide to UCB-sponsored data that will be presented during the AES annual meeting:
Lacosamide
Lacosamide Conversion to Monotherapy for the Treatment of Partial-Onset Seizures: Results from a Historical-Controlled, Multicenter, Double-Blind, Randomized TrialAbstract 1.227; Poster Session 1; Saturday, December 7, 12 6 p.m.
Continue reading here:
New data from UCB's epilepsy portfolio to be highlighted at the 67th Annual Meeting of the American Epilepsy Society